Amber

Brief description of study

A randomized, multicenter, double-masked, vehicle-controlled study to evaluate the safety and efficacy of NEXAGON in subjects with PCED. Will enroll 120 subjects. Those subjects whose defect has not re-epithelialized upon end of the Treatment Period or who achieved re-epithelialization but failed to maintain re-epithelialized for 28 days after treatment completion are eligible to enter the Open-label Treatment Period.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions:
Medical Research
Age: - 99 Years
Gender: All

TBD

Updated on 09 Mar 2024. Study ID: 854355

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).